Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Crisaborole 2% ointment proven safe, effective in hidden, genital and facial psoriasis

01 Feb 2020

Patients with intertriginous, anogenital or facial psoriasis see significant clinical improvements with the use of crisaborole 2% ointment, a nonsteroidal phosphodiesterase 4 inhibitor, according to the results of a study. The topical agent is also well tolerated.

To assess the safety and efficacy of crisaborole 2% ointment, a double-blind, randomized, vehicle-controlled trial was performed in 21 participants with intertriginous, anogenital and facial psoriasis. They were randomly assigned 2:1 to receive 4 weeks of twice-daily treatment with either crisaborole 2% ointment (n=14) or vehicle ointment (n=7), which was followed by 4 weeks of open-label treatment with crisaborole 2% ointment. Disease severity was measured using the Target Lesion Severity Scale (TLSS).

After 4 weeks, participants in the crisaborole group showed substantially greater improvement compared with those in the vehicle group (66 percent vs 9 percent; p=0.0011). This improvement persisted through the open-label phase, exhibiting 81-percent lesional improvement by week 8. Moreover, 71 percent of participants in the crisaborole group achieved clinical clearance.

No adverse events were reported.

This finding was consistent with that of a previous study, which suggested that the application of crisaborole ointment to sensitive skin areas was well tolerated in healthy volunteers, making it a potential topical treatment alternative for patients with psoriasis or atopic dermatitis. [Am J Clin Dermatol 2016;17:519-526]

The present study was limited to a single tertiary care centre and by its small sample size, according to the investigators
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.